Multimodal imaging in neurodegenerative disorders can provide insights on structural, functional and neurochemical alterations that might not be possible via clinical testing alone. New findings on multimodal imaging in idiopathic REM sleep behaviour disorder (iRBD) have implications for the relationship between iRBD, the clinical phenotype of Parkinson disease and the underlying substrate of Lewy body disease, particularly for understanding the pathophysiology and designing disease-modifying therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boeve, B. F. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann. NY Acad. Sci. 1184, 17–56 (2010).
St Louis, E. K. & Boeve, B. F. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin. Proc. 92, 1723–1736 (2017).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 24, 197–211 (2003).
Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618–628 (2018).
Boeve, B. F. Idiopathic REM sleep behaviour disorder in the development of Parkinson’s disease. Lancet Neurol. 12, 469–482 (2013).
Miyamoto, T. et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 67, 2236–2238 (2006).
Iranzo, A. et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 9, 1070–1077 (2010).
Ehrminger, M. et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139, 1180–1188 (2016).
Albin, R. L. et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55, 1410–1412 (2000).
Postuma, R. B., Gagnon, J. F., Bertrand, J. A., Genier Marchand, D. & Montplaisir, J. Y. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 84, 1104–1113 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.F.B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH (UO1 NS 100620, R34 AG056639, U01 AG045390, U54 NS092089, R01 AG041797, P50 AG016574, U01 AG006786 and R44 AG 050326), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. K.K. serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc. She receives research support from Avid Radiopharmaceuticals, Eli Lilly. She is funded by the National Institutes of Health (NIH grants: U01 NS 100620, RF1 AG 57547, P50 AG 16574, U01 AG 045390, R01 NS 80816, RF1 AG 51504, U01 AG 52943, RF1 AG5 5151, R01 AG 55121 and U01 AG 52943) and the Alzheimer’s Drug Discovery Foundation (ADDF).
Rights and permissions
About this article
Cite this article
Boeve, B.F., Kantarci, K. Multimodal imaging in RBD — present and future. Nat Rev Neurol 14, 574–576 (2018). https://doi.org/10.1038/s41582-018-0054-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-018-0054-3